Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News IGM Biosciences Inc IGMS

Healthcare Biotechnology
IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites.... see more

Recent & Breaking News (NDAQ:IGMS)

IGM Biosciences to Participate in Canaccord Genuity Horizons in Oncology Virtual Event

GlobeNewswire April 3, 2020

IGM Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

GlobeNewswire March 26, 2020

IGM Biosciences to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 26, 2020

GlobeNewswire March 19, 2020

IGM Biosciences to Present at Two Upcoming Investor Conferences

GlobeNewswire March 4, 2020

IGM Biosciences to Present at Two Upcoming Investor Conferences

GlobeNewswire February 6, 2020

IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis

GlobeNewswire January 7, 2020

IGM Biosciences to Present at Three Upcoming Investor Conferences

GlobeNewswire November 12, 2019

IGM Biosciences Announces Third Quarter 2019 Financial Results

GlobeNewswire November 7, 2019

IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

GlobeNewswire October 2, 2019

IGM Biosciences Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire September 20, 2019